Full Genome vs Single Gene Testing | Decoding Inflammation

By Alberto Rivera, MD · 2026-05-28 · 6 min read

The Reductionist Trap in Genomic Medicine

The history of clinical genomics has been largely reductionist: identify the gene, characterize the variant, assign the risk. This approach has produced genuine clinical value for monogenic diseases, BRCA1/2 and breast cancer risk, LDLR and familial hypercholesterolemia, HTT and Huntington's disease. In these contexts, single-gene testing captures most of the genomic signal because most of the genomic signal is concentrated in one location.

Chronic inflammatory disease is not a monogenic phenomenon. It is a polygenic one, emerging from the simultaneous interaction of dozens of moderate-effect variants across antioxidant, methylation, detoxification, inflammatory regulatory, and neurotransmitter metabolism pathways. No single gene causes the Oxygen Free Radical Crisis. No single test reveals it. The biology that matters is the biology of interaction.

How Variant Interactions Create Emergent Risk

Consider a patient who carries MTHFR C677T homozygosity alone. Their methylation cycle operates at reduced efficiency, but compensatory pathways, BHMT, MTR, can partly offset the deficit. Their clinical phenotype may be subclinical or mild. Now add COMT Met/Met, reducing the efficiency of the SAMe-dependent catecholamine clearance that already competes with methylation. Add SOD2 Val/Val, compromising mitochondrial antioxidant defense. Add TNF-α -308A, amplifying inflammatory cytokine production in response to every oxidative signal the compromised antioxidant system fails to suppress.

None of these variants alone predicts the clinical picture. Together, they create a compounding biological architecture in which each deficit amplifies every other. This is the genomic reality that single-gene testing systematically fails to capture.

The Network Requires a Network-Level Analysis

Effective genomic medicine for chronic inflammatory disease requires reading the genome as a system, mapping the simultaneous variant burden across all four pathway clusters, identifying the specific nodes of greatest insufficiency, and designing interventions that address the network rather than isolated components within it.

A 2024 multi-omics study in Cell Systems demonstrated that polygenic risk scores incorporating 47 inflammatory pathway variants predicted chronic inflammatory disease burden with significantly higher accuracy than any single-variant or single-pathway model. The predictive signal is in the interaction, and capturing it requires a methodology built for interaction.

This is the foundation of GENEFLAMMATION. Not a panel of selected genes but a comprehensive mapping of the genomic network that governs oxidative and inflammatory biology, read as a system, interpreted as a system, and translated into a therapeutic roadmap that addresses the patient's specific biological architecture rather than the average pattern of their closest diagnostic category.